To guide health-care providers about the role of calcium in peri-and postmenopausal women, The North American Menopause Society recently developed an evidence-based statement.
Anyone who's been practicing ob/gyn for more than 20 years knows that our profession has changed tremendously, and largely to our great frustration.
Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.
Will biological warfare revolutionize the battle against gynecologic cancers? Two experts share the latest molecular tactics using "special" agents. Lethal weapons like Herceptin can throw up some roadblocks, even when they can't always destroy a tumor.
Which may explain why results of studies to determine whether ginger relieves nausea and vomiting have been inconsistent.
Although most cases of mild-to-moderate maternal disease are caused by gestational thrombocytopenia and rarely cause problems, the OB is obliged to rule out more serious causes. And for far-less-common fetal disease, these experts help you differentiate the potentially life-threatening fetal alloimmune thrombocytopenia from a benign drop in platelet count.
Though most of these common tumors are benign, 0.5% of patients undergoing hysterectomy for presumed fibroids will be found to have a leiomyosarcoma, which usually kills within 5 years if it spreads outside the uterus. And five patients' leiomyosarcomas weren't diagnosed until after UAE.
At least that's what Clement J. McDonald, MD, emphasized in an article in the Annals of Internal Medicine (4/4/06). Presenting an actual case, in which two patients were misidentified when a mix-up occurred with their bar-coded identification wristbands, McDonald drew several conclusions to improve risk management
Pressure against the Food and Drug Administration to make a
long-awaited decision on whether to approve the sale of Plan B
(levonorgestrel) without a prescription has been increasing
lately—from the courts and the U.S. Senate.
Aromatase inhibitors have surpassed tamoxifen in treatment of recurrent breast cancer. Will the same be true for early disease? An expert examines the evidence from ongoing clinical trials.